Junshi Biosciences, ESMO Kongresi 2026'da Faz 3 NEOTORCH Çalışmasının Nihai Analiz Sonuçlarını Açıkladı

Junshi Biosciences presented positive final analysis results from its Phase 3 NEOTORCH study at the ESMO Congress 2026. The study evaluated perioperative treatment using toripalimab combined with chemotherapy in patients with resectable stage II-III non-small cell lung cancer. Results demonstrated statistically significant and durable improvements in both event-free survival and overall survival rates. The favorable clinical data reinforces toripalimab's therapeutic potential as an effective treatment option for lung cancer patients. Successful late-stage trials strengthen the company's position within the global oncology biopharmaceutical sector. Continued positive clinical outcomes may pave the way for expanded regulatory approvals and commercial adoption worldwide.